BTT-3033（Cat No.:R064176）is a selective inhibitor of the kinase SIK2 (Salt Inducible Kinase 2), which plays a role in regulating cellular processes such as metabolism, inflammation, and stress responses. By inhibiting SIK2, BTT-3033 has potential therapeutic applications in diseases where SIK2 activity contributes to pathogenesis, such as metabolic disorders, cancer, and inflammatory diseases. Its specificity allows for targeted modulation of the SIK2 pathway, providing a promising approach for drug development. BTT-3033 is currently under investigation in preclinical studies to evaluate its effectiveness and safety in various disease models.